Mouse anti-Human SLPI Monoclonal Antibody | anti-SLPI antibody

SLPI, Human, mAb 31

Cat. Num. AAA584160

• Reactivity: Human
• Applications: Immunoprecipitation, Western Blot, Immunohistochemistry
• Synonyms: SLPI; Monoclonal Antibody; Human; mAb 31; human seminal plasma inhibitor I (HUSI-I); cervix uterine secretion inhibitor (CUSI); bronchial inhibitor (BI); antileukoprotease (ALP) and mucous proteinase inhibitor (MPI); ; anti-SLPI antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Mouse IgG1
• Form/Format: 1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.; For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
• Sequence Length: 132

• Applicable Applications for anti-SLPI antibody: F, Immunoassay (IA), Immunoprecipitation (IP), P, Western Blot (WB), Immunohistochemistry (IHC)
• Application Notes: Application Notes: P: Specimen was fixed in 4% formalin for 4h. Paraffin sections (4 um) were deparifinized, rehydrated; Application Use: For immunohistochemistry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
• Immunogen: SLPI purified from sputum
• Preparation and Storage: Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Immunohistochemistry (IHC)

Related Product Information for anti-SLPI antibody

Product Description: The monoclonal antibody 31 recognizes secretory leukocyte proteinase inhibitor (SLPI). SLPI was identified as an alarm reactant and expression is induced by inflammatory factors like LPS, IL1beta, TNFalpha and neutrophils elastase. SLPI is a relatively small basic antiprotease of 11.7 kDa and is a cationic non-glycosylated protein consisting of 107amino acids. SLPI has a high affinity for the neutrophil serine proteinases, elastase and cathepsin G. Orthologues of SLPI have been found in mice, rate, pigs and sheep. It consists of two highly similar WAP (˜whey acid protein)/four-disulphide core domains. SLPI contain 16 cysteine residues which assemble into eight disulphide bridges (four in each WAP domain). SLPI is constitutively expressed at many mucosal surfaces and is produced by a variety of epithelial cells, including respiratory, intestinal and amniotic epithelia. Expression is also detected in mast cells, neutrophils and macrophages. Expression of SLPI gene is significantly increased by progesterone and by the pro-inflammatory cytokines TNF-alpha and IL1-beta. Although SLPI has been shown to inhibit a spectrum of proteases (including HNE, cathepsin G, trypsin, chymotrypsin and chymase), its main action in this regard is likely to be the inhibition of elastase, as indicated by its low dissociation constant and favourable kinetics of inhibition for this enzyme. SLPI has been described in several body fluids like seminal fluid, bronchial fluids, cervical fluids and saliva. It has been found to be antibacterial, antifungal, anti-retroviral, and to have an important role in mucosal defence. SLPI might also facilitate tumor spread, contributing to wound healing, is elevated in sepsis and levels seem to correlate with oral candidiasis in HIV-1 positive patients. The reactivity of the antibody 31 with isolated domains of SLPI was evaluated using domains obtained by cleavage using partial acidic hydrolysis. Therefore, monoclonal antibody 31 recognizes also other SLPI cleavage products.

References

1. Wingens, M et al; Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol 1998, 111: 996 2. Nakao, R et al; Assessment of oral transmission using cell-free human immunodeficiency virus-1 in mice reconstituted with human peripheral blood leucocyte. Immunology 2003, 109: 271
3. Aarbiou, J et al. Human neuthrophil defensins and secrtory leukocyte proteinase inhibitor in squamous metaplastic epithelium of bronchial airways. Inflamm. Res 2004, 53:230-238
4. Tjabringa, S et al. Host defense effecotr molecules in mucosal secretions. FEMS immunol and med microbial 2005, 45:151
5. Bingle,L et al. WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Resp Res 2006, 7:61
6. Cheng, W et al; Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int J Cancer 2008, 123: 1787
7. Subramaniyam, D et al; Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis. Respirology 2011, 16: 300

NCBI and Uniprot Product Information

• NCBI GI #: 758101
• UniProt Accession #: P03973; P07757; B2R5H8
• Molecular Weight: 14,326 Da
• NCBI Official Full Name: secretory leukocyte protease inhibitor (SLPI)
• UniProt Protein Name: Antileukoproteinase
• Protein Family: Antileukoproteinase
• UniProt Gene Name: SLPI
• UniProt Synonym Gene Names: WAP4; WFDC4; ALP; MPI
• UniProt Entry Name: SLPI_HUMAN

Uniprot Description

SLPI: Acid-stable proteinase inhibitor with strong affinities for trypsin, chymotrypsin, elastase, and cathepsin G. May prevent elastase-mediated damage to oral and possibly other mucosal tissues.

Protein type: Secreted; Inhibitor; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 20q12

Cellular Component: extracellular matrix

Molecular Function: serine-type endopeptidase inhibitor activity; protein binding; enzyme binding; endopeptidase inhibitor activity

Biological Process: negative regulation of viral genome replication; negative regulation of protein binding